Clinical Trial Update: Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating persistence of bactericidal antibodies in adults about four years after a Menactra booster.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Meningococcal Disease
• Meningitis
• Meningococcal Meningitis

Drugs mentioned

• Menactra (Meningococcal conjugate vaccine (A, C, W, Y))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningitis, Meningococcal Meningitis | Phase 4 | Status: COMPLETED | Results posted: 2016-11-07